Eli Lilly's Omvoh meets primary endpoint in Phase 3 pediatric ulcerative colitis trial

• Eli Lilly’s Omvoh met the primary clinical remission endpoint in the Phase 3 SHINE-2 trial in children with ulcerative colitis.
• One-year results showed sustained symptom relief, including corticosteroid-free remission without surgery among patients who responded to initial treatment.
• Lilly plans global regulatory submissions to expand Omvoh’s existing adult indication to pediatric patients ages 6 to 17.
• The findings were presented at United European Gastroenterology Week 2026, marking the first one-year Phase 3 pediatric results for an IL-23p19 inhibitor.
• Safety findings were consistent with Omvoh’s established adult profile, with no new safety signals identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610190440PR_NEWS_USPR_____DE72066) on October 19, 2026, and is solely responsible for the information contained therein.